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Abstract
Purpose Erythropoietin (EPO) and granulocyte colony
stimulating factor (GCSF) have generated interest as novel
therapies after myocardial infarction (MI), but the effect of
combination therapy has not been studied in the large
animal model. We investigated the impact of prolonged
combination therapy with EPO and GCSF on cardiac
function, infarct size, and vascular density after MI in a
porcine model.
Methods MI was induced in pigs by a 90 min balloon
occlusion of the left anterior descending coronary artery. 16
animals were treated with EPO+GCSF, or saline (control
group). Cardiac function was assessed by echocardiography
and pressure-volume measurements at baseline, 1 and
6 weeks post-MI. Histopathology was performed 6 weeks
post-MI.
Results At week 6, EPO+GCSF therapy stabilized left
ventricular ejection fraction, (41±1% vs. 33±1%, p<0.01)
and improved diastolic function compared to the control
group. Histopathology revealed increased areas of viable
myocardium and vascular density in the EPO+GCSF
therapy, compared to the control. Despite these encouraging
results, in a historical analysis comparing combination
therapy with monotherapy with EPO or GCSF, there were
no significant additive benefits in the LVEF and volumes
overtime using the combination therapy.
Conclusion Our findings indicate that EPO+GCSF combi-
nation therapy promotes stabilization of cardiac function
after acute MI. However, combination therapy does not
seem to be superior to monotherapy with either EPO or
GCSF.
Key words Erythropoietin.Granulocyte colony
stimulating factor.Myocardial infarction.Cardiac
remodeling.Cytokine
Introduction
Myocardial infarction (MI) is a leading cause of morbidity
and mortality in Western countries [1]. Despite advances in
the management of MI, the number of patients with
congestive heart failure continues to grow and remains
associated with increased risk of death [1]. Novel thera-
peutic approaches targeted to repairing myocardial damage
have been the focus of intense research over the recent
years [2–5].
Recently, granulocyte colony stimulating factor (GCSF)
and Erythropoietin (EPO) have emerged as promising
candidates for treatment of acute ischemic heart disease.
Despite promising pre-clinical data using GCSF [6, 7],
human clinical trials in acute MI patients, while generally
reassuring in terms of safety, have been disappointing from
the standpoint of clinical benefit, raising questions about
the adequacy of GCSF monotherapy. Nevertheless, we have
recently shown that GCSF therapy mobilizes bone marrow
cells, enhances neovascularization, and prevents further
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DOI 10.1007/s10557-010-6263-7deterioration of LV function in a porcine model of MI with
lower LVEF [8]. In line with our results, a recent meta-
analysis suggests that GCSF may be potentially beneficial
in patients with larger infarcts who have a lower LVEF
(<50%) [9].
EPO has been shown to improve myocardial contractility
[10], reduce cellular damage and apoptosis [11], and
increase neovascularization, leading to reduced infarct size
and improved cardiac function in rodent models of MI [12–
14]. For the first time, our group has recently shown that in
a large animal MI model, prolonged therapy (4 weeks) with
EPO decreases infarct size, mobilizes bone marrow cells,
enhances neovascularization and results in improvements in
ventricular remodeling and function in a porcine model of
acute MI [15].
Given the diversity of cytokines and their overlapping
functions [16–18] and the beneficial effects of EPO and
GCSF therapy post MI, we hypothesized that combination
therapy with EPO and GCSF would enhance angiogenesis,
and decrease infarct size and, therefore, would result in
concomitant improvements in ventricular remodeling and
function in a porcine model of acute MI with reperfusion.
The current manuscript builds on the previous work and
examines whether the combination of EPO and GCSF
would be safe and effective in improving the cardiac
function post-MI. To our knowledge, no prior study has
examined the effect of EPO+GCSF combination therapy
after MI in the large animal model. Of note, since limited
funding was secured for completion of this combination
cytokine study, the current results were compared to
historical and previously published EPO and GCSF mono-
therapy arms [8, 15] by our group. To keep this comparison
appropriate, all aspects of the study amongst the groups
were performed similarly and by the same operators.
Methods
Animals
This study was carried out in accordance with the guide-
lines of the National Institutes of Health with a protocol
approved by the Institutional Animal Care and Use
Committee of University of California San Francisco
(UCSF). Eighteen Yorkshire-Landrace pigs weighing 35–
43 kg were obtained (Pork Power, Turlock, CA) for this
study.
Induction of MI
MI was induced by a 90 min balloon occlusion of the mid
left anterior descending coronary artery (LAD) as previ-
ously published by our group [8, 15, 19]. Briefly, general
anesthesia was induced by intramuscular injection of
ketamine (20 mg/kg), xylazine (2 mg/kg) and atropine
(0.04 mg/kg) then maintained with 2% isoflurane. The
levels of anesthesia were kept the same at all study time
points. Continuous blood pressure, oxygen saturation, and
telemetry monitoring were performed during all procedures.
A 6F sheath was placed in the femoral artery and after
systemic heparinization (100–200 U/kg), the coronary artery
was selectively engaged with a 6F HS0.75 guide catheter. A
standard guide wire was placed in the LAD, and a 2.5 to 3.5×
15 mm coronary angioplasty balloon delivered to the mid
LAD just distal to the second diagonal branch. Balloon
inflation (~4 atm) for 90 min was performed to induce MI.
Complete occlusion with balloon inflation and LAD patency
after balloon deflation was confirmed angiographically.
Intravenous (IV) amiodarone (75 mg over 10 min) and
lidocaine (1 mg/kg IV bolus, followed by 1 mg/min infusion)
were started prior to balloon occlusion, with additional
lidocaine (1–3 mg/kg IV bolus) given at the discretion of the
operatorfor significant ventricular arrhythmias.Animals were
medicated with atenolol (25 mg orally) daily starting 3 days
post-MI. Prior to sacrifice, all animals underwent repeat
coronary angiography.
Treatment protocol
Animals were assigned to one of two treatment groups using
the same protocol previously published by our group testing
EPO and GCSF monotherapy [8, 15]: 1) Long-acting EPO
analog (Aranesp, Amgen, Thousand Oaks, CA) was given as
IV bolus at the time of reperfusion (0.9 ug/Kg), then as
weekly SC injections for 4 weeks (0.4 ug/Kg), and GCSF
(Neupogen, Amgen, Thousand Oaks, CA) was given as IV
bolus at time of reperfusion and then daily SC injections
from day 5 to 9 post MI; and 2) control group (normal saline
in equivalent volume given IV and SC to match the
administration of the EPO therapy group). EPO dosages
were selected following clinical data showing safety and
feasibility with a single bolus of a fixed dose of darbepoetin
[20], clinical studies addressing safety of chronic use of
darbepoetin in patients with chronic renal failure [21], and
pre-clinical data showing improvement in cardiac function
and neovascularization using prolonged EPO therapy in a
dose that did not increase the hematocrit [14]. GCSF dosages
were selected following clinical data showing safety and
feasibility of similar dose post MI [9].
Animal monitoring
Behavior, excreta, attitude (alertness, responsiveness, appe-
tite), signs of respiratory distress (respiratory rate, respira-
tory pattern), motor weakness, and swelling extremities
were monitored daily for the length of study. Arterial blood
410 Cardiovasc Drugs Ther (2010) 24:409–420pressure was monitored at baseline, immediately post
reperfusion, one, and 6 weeks post MI.
Blood sampling and laboratory analysis
Whole blood samples were collected at baseline (prior to
MI), at 2 h, on week one to four after MI induction, and
then at sacrifice. Hemoglobin, hematocrit, white blood
count, creatinine levels, creatine kinase MB fraction (CK-
MB), and troponin I (TnI) were measured by the animal
core laboratory (IDEEX, Sacramento, CA).
Echocardiography
Transthoracic echocardiography (TTE) was performed at
baseline, 1 and 6 weeks after MI using an Acuson 128XP
machine with S3 (1–3 MHz) and S8 (3–8 MHz) probes
(Siemens, Malvern, PA) as previously published by our
group [8, 15, 19]. Long- and short-axis parasternal views
and 4- and 2- chamber apical views were acquired. Left
ventricular end-diastolic volume (LVEDV), end-systolic
volume (LVESV), and ejection fraction (LVEF) were
measured using the area/length method. The wall motion
index (WMI) was calculated, using the method previously
described by the American Society of Echocardiography
[22], by grading the standard 17 myocardial segments
(normal=1, hypokinesis (reduced endocardial motion and
wall thickening in systole) =2, akinesis (absence of inward
endocardial motion or wall thickening in systole) =3,
dyskinesis (outward motion or “bulging” of the segment
in systole, usually associated with thin, scarred myocardi-
um) =4, aneurysm=5), and dividing the sum of the scores
by the number of segments visualized. For all above
parameters, at least three loops per scan were selected and
the results presented as an average of the readings.
Readings were made by blinded operators. The inter-
observer variability (made from different readings of recorded
loops) expressed using coefficient of variation in the
measurement of LVEDV and LVESV was 4.3 +/- 5.7 mL
and 1.4 +/- 2.9 mL, respectively, corresponding to variability
inabsoluteLVEFof2+/-3%.Theintraobservervariabilityfor
WMSI (mean difference between measures 1 and 2) was
1.9%, while the interobserver variability (mean difference
between observers 1 and 2) was 2.5%.
Left ventricular pressure-volume (PV) data were collect-
ed at baseline, 1 week, and 6 weeks after MI as previously
published by our group [8, 15, 19]. Conductance and
pressure signals were acquired using a dual field 5F 12-
electrode pigtail PV catheter (Millar Instruments, Houston,
TX) connected to a Leycom CFL-512 console (CD
Leycom, Zoetermeer, Netherlands) via a TC-510 (Millar)
pressure control unit and a patient module (CD Leycom) as
previously described [19].
Pressure volume measurements
The ventricular end-systolic and end-diastolic pressure-
volume relationships are considered as gold standards in the
characterization of intrinsic ventricular pump properties
[23–25]. In this study, the PV catheter was inserted in the
long axis of the left ventricle and oriented with segment one
in the apex and segment seven in the aortic outflow as
previously reported [8, 15, 19]. Inferior vena cava (IVC)
occlusion was performed with a 7F, 34 mm Amplatzer
sizing balloon (AGA Medical, Plymouth, MN) introduced
via the femoral vein, inflated for 6–10 s to achieve ~50%
drop in arterial blood pressure. Continuous data were
acquired at a sampling frequency of 250 Hz during the
steady state and IVC occlusion.
PV data were analyzed offline using the Conduct NT
software (CD Leycom) by a blinded operator with a 10 Hz
filter as previously described [19, 26]. Briefly, data were
Fig. 1 Enzymatic curve for CK-MB and Troponin I. a CK-MB (ug/ml);
each line represents the mean of one experimental group. b Troponin I
(ug.ml); each line represents the mean of one experimental group. Both
e n z y m e sw e r es i g n i f i c a n t l yi n c r e a s e d2hp o s tM I ,r e t u r n i n gt ob a s e l i n e
at 6 weeks. There were no differences between EPO+GCSF and Control
in each one of the time-points
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on volumes derived from transthoracic echocardiographic
images collected at the beginning of each case. Using
conductance data, and the α and Vc calculations, the Conduct
NT software calculated ventricular volumes as previously
described [27]. Steady state data included heart rate (HR),
maximum rate of pressure change in systole (dP/dtmax),
decline with relaxation (dP/dtmin), left ventricular end-
diastolic pressure (LVEDP), end-systolic pressure (LVESP),
LVESV, and LVEDV. Stroke volume (SV) was recorded as
LVEDV—LVESV, cardiac output (CO) as SV×HR, LVEF
as SV/LVEDV, and stroke work (SW) as the area enclosed
by the PV loop.
Diastolic function was evaluated during steady state by the
time constant of isovolumic relaxation, τ,a n dt h ed P / d t min. τ
was computed as described by Raff and Glantz using
pressure recorded during the isovolumetric relaxation period
which is the period from the time of dP/dtmin to the time
when left ventricular pressure falls to 5 mmHg above the
end-diastolic pressure of the following beat [28]. τ was
calculated as the negative inverse of the linear slope of dp/dt
vs. pressure during this period.
D a t ao b t a i n e dd u r i n gI V Co c c l u s i o nw e r eu s e dt o
calculate the linear end-systolic pressure-volume relation
(characterized by the slope; also called end-systolic
elastance (Ees) and an intercept, V0, and the preload
recruitable stroke work (PRSW, or slope of SW versus
LVEDV curve) [29].
Parameter Control (n=8) EPO±GCSF (n=8) t Test
a
LVEF (%)
Baseline 55.2 (1.2) 56.8 (1.3) NS
1 Week post MI
b 41.3 (2.1)** 41.1 (1.6)** NS
6 Weeks post MI
b 33.2 (1.5)**, *** 41 (1.2)** p<0.01
Repeated measures ANOVA (main effect) p<0.01 p<0.01
LVEDV (mL)
Baseline 52.2 (1.9) 53.2 (0.9) NS
1 Week post MI
b 63.5 (2)** 62.5 (1.5)** NS
6 Weeks post MI
b 73.5 (2.5)**, **** 67.9 (2)**, ****, **** p=0.04
Repeated measures ANOVA (main effect) p<0.01 p<0.01
LVESV (mL)
Baseline 23.6 (1.2) 22.9 (0.9) NS
1 Week post MI
b 37.2 (1.8)** 36.8 (1.2)
** NS
6 Weeks post MI
b 49.5 (1.9)**, **** 40.7 (1.5)
** p=0.01
Repeated measures ANOVA (main effect) p<0.01 p<0.01
WMI
Baseline 1 1
1 Week post MI
b 1.7 (0.1)** 1.6 (1)** NS
6 Weeks post MI
b 1.9 (0.1)**, **** 1.6 (1)** p<0.01
Repeated measures ANOVA (main effect) p<0.01 p<0.001
HR (bpm)
Baseline 79 (4) 84 (7) NS
1 Week post MI
b 84 (6) 87 (4) NS
6 Weeks post MI
b 87 (6) 83 (6) NS
Repeated measures ANOVA (main effect) NS NS
Table 1 Echocardiographic
parameters over time
The values are expressed as
the mean±standard error
(in parentheses)
LVEF left ventricle ejection frac-
tion, LVEDV LV end-diastolic
volume, LVESV LV end-systolic
volume, WMI wall motion index,
HR heart rate
NS Non significant
aSignificance of differences
“between groups” was tested
by an unpaired t test
bChange from baseline value;
significance of post-hoc test in
repeated measures ANOVA design
*p<0.05vs. baseline,
** p < 0.01
vs. baseline,
***p<0.05 vs. 1 week,
****p<0.01 vs. 1 week
Fig. 2 Leukocyte response to cytokine therapy. EPO+GCSF combi-
nation therapy induced a significant increase in WBC 1 week after MI
compared to baseline and Control group (both, # P<0.01)
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All animals were sacrificed 6 weeks after MI and their
hearts excised, weighed, and any gross surface abnormal-
ities recorded. Histological and immunohistochemistry was
performed in a blinded manner by CV Path Institute, Inc,
MD. The ventricles were serially sliced at approximately
1 cm intervals parallel to the posterior atrioventricular
sulcus from the apex to the base as previously describe by
our group [8, 15, 19]. The thickness of each slice was
measured and recorded. Digital images were taken for
morphometric analysis of LV area, infarct size, and
thickness, using IPLab software (Scanalytics, Rockville,
MD). Infarct size was defined as a thinned and pale region
of the anterior LV wall [30] and did not account for areas of
viable tissue. Myocardial tissue for paraffin embedding was
taken from the basal, mid, and apical-cavity levels. The
three levels were then divided clockwise, beginning with
the interventricular groove, into sixteen segments as
described before [31]. Myocardial sections were transferred
to 15% sucrose, dehydrated in a graded series of alcohols,
and embedded in paraffin. Sections (4-5 μm) were mounted
on charged slides and stained with hematoxylin and eosin,
Masson’s Trichrome to evaluate for fibrosis using the IPLab
software. The fibrotic areas from the 16 ventricle segments
were summed and presented as a percent of the total LV
area. The infarct zone (IZ) was defined as the arc of the left
ventricle containing scar tissue.
For vessel density, myocardial tissue for paraffin
embedding was taken from the basal, mid, and apical
levels, and sectioned circumferentially into 4 adjacent
transmural areas to include the central area of infarction, 2
adjacent border areas (border zone for capillary and
arteriole measurements were defined at sites 1.2 mm and
2.0 mm outside the zone of infarction), and a control non-
infarcted region (remote zone).
Immunohistochemical staining with a biotinylated lectin
antibody (Dolichos biflorus, DBA, Sigma, St. Louis, MO)
was used for the identification of capillaries. A monoclonal
antibody against smooth muscle actin clone 1A4 (dilution
1:2000, Sigma) was used for the identification of vascular
smooth muscle cells for identification of arteries and
arterioles. Vascular density was measured at mid-ventricle
region, in six to nine high power fields per section.
Capillary (200X magnification), artery and arteriolar
(100X) density were measured and expressed as the mean
Fig. 3 Changes in LV function and volumes over time following
myocardial infarction by echocardiography. a Left ventricular ejection
fraction (LVEF); each line represents the mean of one experimental
group. LVEF continue to decrease in controls, while combination
therapy stabilizes LVEF. b Wall motion index does not differ at
1 week, but is better on the EPO+GCSF therapy compared to control
at 6 weeks c End systolic volume and d end diastolic volume at
6 weeks post-MI. Data are shown as mean±SEM
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Parameter Control (n=8) EPO±GCSF (n=8) t Test
a
HR (bpm)
Baseline 80 (3) 86 (5) NS
1 Week post MI
b 83 (3) 85 (4) NS
6 Weeks post MI
b 88 (5) 92 (3) NS
Repeated measures ANOVA (main effect) NS NS
MAP(mmHg)
Baseline 82 (4) 85 (3) NS
1 Week post MI
b 80 (6) 88 (4) NS
6 Weeks post MI
b 86 (8) 85 (5) NS
Repeated measures ANOVA (main effect) NS NS
LVESP (mmHg)
Baseline 86 (2) 89 (5) NS
1 Week post MI
b 90 (4) 93 (3) NS
6 Weeks post MI
b 76 (3)*
, **** 84 (4) NS
Repeated measures ANOVA (main effect) p<0.02 NS
LVEDP (mmHg)
Baseline 3.1 (0.3) 2.9 (0.5) NS
1 Week post MI
b 9.9 (1.4)** 8.8 (1.1)** NS
6 Weeks post MI
b 6 (0.5)*
, **** 4.3 (1.1)**** NS
Repeated measures ANOVA (main effect) p<0.01 p<0.01
SV (mL)
Baseline 28.6 (1) 30.4 (0.7) NS
1 Week post MI
b 26.3 (1.5) 25.7 (1.3)* NS
6 Weeks post MI
b 21.4 (0.7)**, **** 27.7 (1.4) p<0.01
Repeated measures ANOVA (main effect) p<0.01 p=0.03
Ees (mmHg/ml)
Baseline 1.7 (0.2) 1.4 (0.2) NS
1 Week post MI
b 1.2 (0.3) 1.8 (0.3) NS
6 Weeks post MI
b 1.6 (0.3) 1.7 (0.2) NS
Repeated measures ANOVA (main effect) NS NS
Vo intercept (ml)
Baseline -37.2 (7) -42.9 (10) NS
1 Week post MI
b -25.9 (6) -28 (5) NS
6 Weeks post MI
b 11.4 (5)**, **** -11 (6)** p<0.01
Repeated measures ANOVA (main effect) p<0.01 p<0.01
PRSW (mmHg)
Baseline 53 (3) 51 (1) NS
1 Week post MI
b 41 (2)** 40 (2)** NS
6 Weeks post MI
b 34 (1)**, *** 41 (2)** p<0.05
Repeated measures ANOVA (main effect) p<0.01 p<0.01
dP/dtmax(mmHg/s)
Baseline 1270 (65) 1255 (42) NS
1 Week post MI
b 1035 (53)** 1020 (36)** NS
6 Weeks post MI
b 842 (38)**, **** 1038 (20)** p<0.01
Repeated measures ANOVA (main effect) p<0.01 p<0.01
dP/dtmin(mmHg/s)
Baseline - 1156 (18) -1168 (20) NS
1 Week post MI
b - 1024 (37)** -1068 (23)** NS
6 Weeks post MI
b - 890 (30)**, **** -1035 (21)** p<0.01
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2. The measured total
tissue area was corrected for remaining interstitial space.
Statistical analysis
All results are expressed as means±standard error of the
mean (SEM). A repeated measures ANOVA model (Sigma-
Stat 3.5, Systat Software, San Jose, CA) was used to test
the responses of examined parameters (measured at
baseline, week1 and 6) in the experimental variants
(Control, EPO+GCSF). The within-subject design included
an overall F test of the main effects and then a post-hoc
pairwise comparison of the values measured at 1 week and
6 weeks against the baseline, and 6 weeks against 1 week,
using the Holm-Sidak method. Significance of differences
between groups (Control, EPO+GCSF) was tested by an
unpaired t test. A historical analysis using repeated
measures ANOVA model (SigmaStat 3.5, Systat Software,
San Jose, CA) was used to test the responses of examined
parameters (measured at baseline, week1 and 6) in all
experimental variants (EPO+GCSF). Correlations were
performed using the Person method. A p<0.05 was
considered statistically significant in all the employed tests.
Results
Two animals died during creation of the MI model, leaving
sixteen animals for the study. Patency of the coronaries was
confirmed by angiography post reperfusion in all remaining
animals. Mean arterial pressure immediately after reperfu-
sion remained stable compared to baseline and did not
differ between groups (mean 83±4 at baseline vs. 81±4
after reperfusion, p=NS). No adverse clinical events related
to the drugs were noted during the study, including
thromboembolic events and hypertension. CRP levels
remained stable over time in both groups. As shown on
Fig. 1, CK-MB and TnI levels did not differ between groups
and, as expected, were significantly elevated two hours after
the induction of the MI, returning to baseline thereafter
(mean CK-MB 3.8±1.9 to 29.2±7.1 μg/L, p<0.01; and
mean TnI 0.48±0.07 to 22.5±2.3 μg/L, p<0.01). All
animals underwent repeat coronary angiography prior to
sacrifice at the end of the study and LAD patency was
documented. No differences in collateral circulation com-
pared to baseline angiography or amongst the groups were
present.
Cytokine therapy mobilizes bone marrow cells
EPO+GCSF group had significantly increased WBC counts
at 1 week post-MI (Fig. 2). The mononuclear fraction count
(lymphocytes plus monocytes) were also significantly
higher at 1 week post-MI on the EPO+GCSF group
compared to baseline (p<0.01) and to Control (respectively,
12.6±0.5 vs. 8.7±0.7 10
6 cells/ml), p<0.01 At week 4
post-MI, EPO+GCSF therapy induced a significant increase
in the hemoglobin levels compared to baseline (respective-
ly, 10.8±0.4 to 13.8±0.6 g/dl; p<0.01).
Echocardiographic parameters: EPO+GCSF preserves
LVEF and prevents LV dilation over time
Echocardiographic parameters are shown in Table 1.A t
6 weeks post-MI, EPO+GCSF group stabilized LVEF, while
the control group demonstrated a statistically significant
further deterioration of function (0±1 vs. -7±1%, p<0.01vs.
control) compared to week 1 post MI (Fig. 3a). The wall
Table 2 (continued)
Parameter Control (n=8) EPO±GCSF (n=8) t Test
a
Repeated measures ANOVA (main effect) p<0.01 p<0.01
τ (ms)
Baseline 57 (1) 56 (1) NS
1 Week post MI
b 69 (4)** 64 (2)** NS
6 Weeks post MI
b 62 (1)*, *** 56 (1)**** p<0.01
Repeated measures ANOVA (main effect) p<0.01 p<0.01
The values are expressed as the mean± by standard error (in parentheses)
HR heart rate, MAP mean arterial pressure, LVESP left ventricular end-systolic pressure, LVEDP left ventricular end-diastolic pressure, SV stroke
volume, Ees linear end-systolic pressure-volume relation or end-systolic elastance, V0 Volume zero Ees intercept, PRSW preload-recruitable stroke
work, dP/dtmax maximum rate of change of left ventricular pressure with time, dP/dtmin peak of pressure decay, τ time constant of isovolumic
relaxation, MI myocardial infarction
NS Non significant
aSignificance of differences “between groups” was tested by an unpaired t test
bChange from baseline value; significance of post-hoc test in repeated measures ANOVA design *p<0.05 vs. baseline, **p<0.01 vs. baseline, ***p<0.05
vs. 1 week, ****p<0.01 vs. 1 week
Cardiovasc Drugs Ther (2010) 24:409–420 415motion score was better in the EPO+GCSF group compared
to the control (Fig. 3b), corroborating the LVEF findings.
LVESV and LVEDV were also lower in the EPO+GCSF
group at 6 weeks compared to the control (Fig. 3c and d).
PV-loop parameters: Cytokine therapy prevents further
impairment of systolic function after AMI
The hemodynamic parameters are summarized in Table 2.
At 6 weeks, there was a significant increase in SV in the
EPO+GCSF group compared to control (27.7±1.4 vs.
21.4±0.7, p<0.01) (Fig. 4). Moreover, the peak positive
dP/dt in the EPO+GCSF group was higher than the control
group. The linear Ees was unchanged overtime and did not
differ between groups, but there was a significant
difference in the rightward movement of the V0,i n d i c a t i n g
increased heart size in the control group in comparison to
EPO+GCSF therapy (Fig. 4). As previously reported by us
and others [19, 32, 33], the non-significant changes in the
slope of the Ees could be a result of changes in loading
conditions, LV dimensions, and regional morphological
changes which are difficult to evaluate with the conduc-
tance catheter method over time but these reflect what we
expect to see in clinical settings. On the other hand, the
slope of the PRSW is a reasonable linear, afterload-
independent relationship, and a well-described contractil-
i t yi n d e xi ni n t a c ta n i m a lm o d e l s[ 29]. In our study, the
Fig. 4 EPO+GCSF preserves hemodynamics over time. Representative
steady-statePVloopsfromoneanimalatbaseline(blue), 1 week post-MI
(red) and 6 weeks post-MI (green)f r o mC o n t r o la and EPO+GCSF
combination therapy b. After infarction, the PV loops narrowing is more
evident in the Control animals compare to the EPO+GCSF group,
indicating reduction in stroke work, and shift rightward due to
increasing volumes (black arrows)
Fig. 5 Extent offibrosis followingmyocardial infarction.a EPO+GCSF
treatment is associated with decreased fibrosis of the left ventricle
compared to the control group. Representative infarct zone regions (arc
of the left ventricle containing scar tissue) stained with Masson
Trichrome (fibrosis=blue) in sections of b Control, c EPO+GCSF.
Data are mean±SD
416 Cardiovasc Drugs Ther (2010) 24:409–420PRSW was significantly decreased at 1 weeks after MI in
the control group compared to EPO+GCSF therapy.
EPO+GCSF positively impacts diastolic function
As summarized in Table 2, peak negative dP/dt was
significantly lower in the EPO+GCSF group compared to
the control. Also, the Tau constant was smaller in the
EPO+GCSF group compared to the control pointing
towards a beneficial effect of the EPO+GCSF cytokine
therapy on diastolic function.
Cytokine therapy leads to more viable myocardium
Measurements derived from gross images of serial myo-
cardial slices suggested that compared with the control
group, treatment with EPO+GCSF did not lead to a
reduction in the infarct size (16±4 vs.15±3%, p=ns).
However, histological evaluation by Masson’s Trichrome
staining revealed an overall decrease in scar and fibrosis
(Fig. 5a, p<0.01) in the EPO+GCSF group compared to the
control, and therefore, more viable myocardium. The
differences between the two techniques rely on the fact
that the gross pathology evaluation does not take into
account areas of viable tissue within the infarct zone, which
are prevalent in this ischemia reperfusion model and
contribute to the myocardial wall motion.
Cytokine combination therapy increases vascular density
As shown in Fig. 6a-c, capillary density at the infarct
border zone was increased in EPO+GCSF treated animals
compared to control (p<0.01) as was the arteriolar density
(p<0.01, Fig. 6d-e).
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Fig. 6 Effect of cytokine therapy on vascular density. a EPO+GCSF
therapy resulted in increased capillary density in the infarct border
zone compared to control. Representative infarct border zone areas
stained with antibodies against lectin (pink) in sections of b control vs.
c EPO+GCSF. Scale bar=200 μm. d EPO+GCSF results in increased
arteriole density at the infarct border zone compared to control.
Representative infarct border zone areas stained with antibodies against
smooth muscle actin (pink) in sections of e control vs. f EPO+GCSF
treated pigs. Scale bar=100 μm
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arteriolar density at infarct zone compared to control
(respectively, 1058±259 vs. 508±56 capillaries/mm
2, p<
0.01; 27.5±6.8 vs.13.7±6 arterioles/mm
2, p<0.01). Capil-
lary density at the infarct zone and LVEF at 6 weeks also
showed significant correlation (r=0.84; p<0.01).
Historical analysis shows non-superiority of EPO+GCSF
combination therapy over monotherapy
In a historical analysis comparing monotherapy with EPO
and GCSF recently published by our group [8, 15], and
EPO+GCSF combination therapy, there was no significant
differences in the LVEF and volumes overtime (Table 3).
Therefore, although combination therapy seems to be safe
and effective, it does not seem to be superior to mono-
therapy with either EPO or GCSF.
Discussion
The major findings of this study are: [1] EPO+GCSF
combination therapy is safe; [2] EPO+GCSF stabilizes
systolic function and prevents further deterioration of
diastolic cardiac function post-MI; [3] EPO+GCSF therapy
induces bone marrow cell mobilization; [4] EPO+GCSF
leads to more viable myocardium and increased vascular
density compared to the control group; [5] EPO+GCSF
combination therapy does not seem to be superior than EPO
or GCSF monotherapy in a historical post hoc analysis.
To our knowledge, this is the first report of EPO+GCSF
combination therapy in the large animal acute MI model. In
this study, we have used doses that our group tested as
monotherapy in the same animal model [8, 15], and that
have been approved for clinical use, demonstrating that
combination therapy was safe and effective. The mild
increaseinthehemoglobinlevelat4weeks(peakof13.8g/dl)
wasnotassociatedwiththromboemboliceventsandtheuseof
EPO was not associated with hypertension in the treated
animals.
In our model, we found that EPO+GCSF combination
therapy stabilized systolic function, and reduced post-MI
remodeling by diminishing LV diastolic dilatation and
pressures over time. Combination therapy also resulted in
more viable myocardium and the better wall motion score
corroborated this finding, demonstrating preservation of the
wall motion at the infarcted area. In addition, EPO+GCSF
combination therapy was associated with increased capil-
lary and arteriolar density. This ability to promote revascu-
larization may partly explain the results as previously
demonstrated by us and others [12, 34, 35].
Interestingly, when we performed a historical compari-
son between combination therapy and our previous reports
using EPO or GCSF as monotherapy [8, 15], all three
therapeutic strategies were superior compared to the control
arm. However, we could not demonstrate a clear and
significant additive or synergistic effect on cardiac function
with EPO+GCSF combination therapy over monotherapy.
EPO+GCSF combination therapy has proven useful in
the treatment of patients with refractory anemia due to
myelodysplastic syndrome by a synergistic inhibition of
progenitor cell apoptosis, [36] and possibly by enhance-
ment of stem cell mobilization [37]. We have recently
evaluated the mobilization of Lin–/Sca-1+/c-kit+ cells from
Parameter EPO±GCSF (n=8) EPO (n=8) GCSF (n=8) ANOVA F test
LVEF (%)
Baseline 56.8 (1.3) 57.7 (0.8) 56.6 (0.6) NS
1 Week post MI
a 41.1 (1.6)* 43.8 (0.7)* 42.8 (1.5)* NS
6 Weeks post MI
a 41 (1.2)* 39.3 (2.5)*, *** 38.4 (2.1)*, *** NS
Repeated measures
ANOVA (main effect)
p<0.01 p<0.01 p<0.01
LVEDV (mL)
Baseline 53.2 (0.9) 53.2 (2) 49.6 (1.2) NS
1 Week post MI
a 62.5 (1.5)* 63.5 (2.5)* 60.7 (2.1)* NS
6 Weeks post MI
a 67.9 (2)*, ** 70.8 (2.1)*, *** 70.5 (1.7)*, *** NS
Repeated measures
ANOVA (main effect)
p<0.01 p<0.01 p<0.01
LVESV (mL)
Baseline 22.9 (0.9) 22.6 (0.9) 21.3 (0.4) NS
1 Week post MI
a 36.8 (1.2)* 35.6 (1.6)* 34.4 (1)* NS
6 Weeks post MI
a 40.7 (1.5)* 43.1 (3.2)*, *** 44 (2.3)*, *** NS
Repeated measures
ANOVA (main effect)
p<0.01 p<0.01 p<0.01
Table 3 Post hoc analyis-
nonsuperiority of combination
versus monotherapy over time
The values are expressed as
the mean± by standard error
(in parentheses)
LVEF left ventricle ejection frac-
tion, LVEDV LV end-diastolic
volume, LVESV LV end-systolic
volume
NS Non significant
aChange from baseline value;
significance of post-hoc test in
repeated measures ANOVA design
*p<0.01 vs. baseline, **p<0.05
vs. 1 week, ***p<0.01 vs.
1w e e k
418 Cardiovasc Drugs Ther (2010) 24:409–420the bone marrow into the circulation post-MI in the eGFP+
chimeric mouse model, and demonstrated that combination
of EPO+GCSF therapy resulted in significantly increased
mobilization of Lin
–/Sca-1
+/c-kit
+ cells into the circulation
at 6 days post-MI compared with either EPO or GCSF
monotherapy, or to control [38]. However, similar to this
current report in the large animal MI model, EPO and
GCSF combination therapy did not seem to have an
additive benefit of combination therapy over monotherapy
with either agent in the rodent MI model either [38].
There are a number of limitations that need to be pointed
out in this study. Given the difficulties with housing large
animals at our facility and the cost associated with such
studies, the duration of follow-up and the number of
animals/group had to be limited and only selected doses
of the agents used could be studied. The follow-up time
point in the current study was chosen based on previous
pre-clinical investigations that demonstrated functional
improvements by this time which plateau thereafter and to
keep the design of the experiment consistent with our prior
reports with the monotherapy arms [8, 15] to allow direct
comparison [39]. We recognize that 6 weeks may be too
short to encompass the complete evolution of cardiac
remodeling and heart failure but longer study durations
are very challenging to undertake in the large and growing
porcine animal model.
In addition, the doses of these agents were chosen
because of the safety profile in clinical settings. Clearly,
different doses and combinations thereof could be studied
but the cost of such a study in large animals would be
prohibitive. Importantly, our study has limited ability to
define the intrinsic mechanisms responsible for the im-
proved cardiac function with EPO+GCSF combination
therapy vs. control. These detailed mechanistic questions
are difficult to answer in large animal models and are
outside the scope of this current report. Notably, we could
not overcome the lack of well recognized porcine anti-
bodies to characterize bone marrow progenitor cells both in
the circulation and also in the heart. Finally, given the large
size of the porcine hearts and the infarcted regions, accurate
analyses for differential apoptosis are difficult to make in
this model and as such were not undertaken in this study.
In conclusion, we report that prolonged combination
therapy with EPO+GCSF in a large animal model of acute
MI with reperfusion has beneficial effects on left ventricular
functionand structure.EPO+GCSF combination therapy after
acute MI led to an increase in viable myocardium, increased
vascular density, and promoted stabilization of LV global
functionandimprovedindicesofLVremodeling.Infollow-up
to a previous report from our laboratory using EPO or GCSF
monotherapy post-MI in the large animal model, combination
cytokine therapy with EPO+GCSF does not seem to be
superior to monotherapy with either agent alone.
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